Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AURA3: osimertinib versus platinum-pemetrexed chemotherapy in T790M-positive advanced non-small cell lung cancer after prior EGFR TKI
2014-000594-39Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of osimertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Started Jul 2014; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-000594-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000594-39.